



ARUNJYOTI Bio VENTURES Ltd.

To,

Date: 13.02.2019

BSE Limited,
P.J. Towers, Dalal Street,
Mumbai-400001

Dear Sir/Madam,

Sub: Outcome of Board meeting held on 13.02.2019

Ref: Scrip Code 530881

With reference to the subject cited, this is to inform the Exchange that at the meeting of the Board of Directors of Arunjyoti Bio Ventures Limited (formerly Century 21st Portfolio Limited) held on Wednesday, 13.02.2019 at the registered office of the company, the Un - Audited financial results for the quarter ended 31.12.2018 alongwith Limited Review Report was considered and approved:

The meeting concluded at 4:30 p.m.

This is for the information and records of the Exchange, please.

Thanking you.

Yours faithfully,

For Arunjyoti Bio Ventures Limited
(formerly Century 21st Portfolio Limited)

CH Ramamohan Challa

Ramamohan Challa
Whole-Time Director
DIN: 08300174

Encl: as above

ARUNJYOTHI BIO VENTURES LIMITED

Statement of Un-Audited Results for the Quarter Ended and Nine Months Ended 31.12.2018

Amounts in Lakhs

S.No.	Particulars	For the Quarter ended			Nine Months Ended		Year Ended
		31.12.2018	30.09.2018	31.12.2017	31.12.2018	31.12.2017	31.03.2018
I.	Revenue from Operations	175.96	36.48	-	212.43	4.66	4.66
II.	Other Income	0.11	-	-	0.11	-	-
III.	Total income (I+II)	176.07	36.48	-	212.55	4.66	4.66
IV.	Expenses						
	(a) Cost of Materials consumed	-	-	-	-	-	-
	(b) Purchase of stock-in-trade	150.90	59.92	-	210.82	2.81	2.91
	(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	-31.33	-27.58	-	-58.91	-	-
	(d) Employee benefits expense	6.27	4.50	0.59	10.70	2.22	3.62
	(e) Finance Cost	0.003	0.01	-	0.01	-	0.10
	(f) Depreciation and amortisation expense	-	-	0.10	-	0.30	0.31
	(h) Other expenses	7.16	1.72	9.19	8.96	21.90	22.43
	Total Expenses	132.99	38.57	9.88	171.57	27.23	29.37
V.	Profit / (Loss) before and exceptional items and Tax (III-IV)	43.08	(2.09)	(9.88)	40.97	(22.57)	(24.71)
VI.	Exceptional Items	-	-	-	-	-	-
VII.	Profit / (Loss) from before tax (V-VI)	43.08	(2.09)	(9.88)	40.97	(22.57)	(24.71)
VIII.	Tax expense						
	Current Tax	-	-	-	-	-	-
	Deferred Tax	-	-	-	-	-	-
IX.	Net Profit / (Loss) after Tax (VII-VIII)	43.08	(2.09)	(9.88)	40.97	(22.57)	(24.71)
X.	Other Comprehensive Income	-	-	-	-	-	-
	Items that will not be reclassified to Profit or Loss	-	-	-	-	-	-
	Items that will be reclassified to Profit or Loss	-	-	-	-	-	-
XI.	Total Comprehensive Income	43.08	(2.09)	(9.88)	40.97	(22.57)	(24.71)
XII.	Paid-up equity share capital (Face Value of Rs. 10/- per share)	207.09	207.09	207.09	207.09	207.09	207.09
XIII.	Earnings Per Equity Share of face value of Rs.10/- each)						
	a) Basic & Diluted (In Rs.)	2.08	(0.10)	(0.48)	1.98	(1.09)	(1.19)

NOTES:

- The above results were reviewed by the Audit Committee of Directors and taken on record by the Board of Directors at their meeting held on 13.02.2019
- These results have been prepared in accordance with the recognition and measurement principles laid down in the Ind AS- 34 "Interim Financial Reporting" prescribed under Section 133 of Companies Act, 2013 read with the relevant rules issued thereunder and other accounting pronouncements generally accepted in India.
- The Company is engaged in "Trading of Hardware items and Agriculture Inputs" operating hence there are no separate reportable segments as per Ind AS -108 "Operating Segments".

For ARUNJYOTHI BIO VENTURES LIMITED

Place : Hyderabad
Date : 13.02.2019

Managing Director



ARUNJYOTHI BIO VENTURES LIMITED

BALANCE SHEET AS AT 31st DECEMBER 2018

(Amount in Lakhs)

	PARTICULARS	As at December 31, 2018	As at March 31, 2018
I	ASSETS:		
(1)	Non-current assets		
	(a) Property, Plant and Equipment	-	-
	(b) Capital work-in-progress	-	-
	(c) Goodwill	-	-
	(d) Other Intangible Assets	-	-
	(e) Intangible Assets under development	-	-
	(f) Financial assets	-	-
	(i) Investments	-	-
	(ii) Other Financial Assets	177.56	177.56
	(g) Deferred tax assets (net)	-	-
	(h) Other non-current assets	-	-
(2)	Current assets		
	(a) Inventories	58.91	-
	(b) Financial assets		-
	(i) Investments	-	-
	(ii) Trade receivables	144.16	451.32
	(iii) Cash and cash equivalents	41.29	324.61
	(iv) Bank Balances other than (iii) above	-	-
	(v) Loans and advances	-	-
	(vi) Investments held for Sale	-	-
	(c) Other current assets	75.02	74.22
	TOTAL ASSETS	496.94	1,027.71
II	EQUITY AND LIABILITIES:		
	Equity		
	(a) Equity Share Capital	207.09	207.09
	(b) Other Equity		-
	(i) Reserves and Surplus	6.59	-34.38
	Liabilities		
(1)	Non Current Liabilities		
	(a) Financial Liabilities		-
	(i) Borrowings	-	19.35
	(b) Provisions	-	-
(2)	Current Liabilities		
	(a) Financial Liabilities		-
	(i) Borrowings	-	-
	(ii) Trade Payables	157.72	701.33
	(iii) Other financial liabilities	-	-
	(b) Other current liabilities	125.54	133.14
	(c) Provisions	-	1.18
	(d) Deferred tax liabilities(Net)	-	-
	TOTAL EQUITY AND LIABILITIES	496.94	1,027.71

For ARUNJYOTHI BIO VENTURES LIMITED

Place : Hyderabad

Date : 13.02.2019

Managing Director





M M REDDY & CO.,
Chartered Accountants

Phone : 040-23418836
040-40272617
Mobile : 98482 71555

LIMITED REVIEW REPORT

To,
The Board of Directors,
ARUNJYOTI BIO VENTURES LIMITED

We have reviewed the accompanying statement of Un-audited Financial Results of **ARUNJYOTI BIO VENTURES LIMITED** or the quarter ended **31st December, 2018** attaching herewith, being submitted by the company pursuant to the requirements of Regulation 33 of the SEBI (Listing obligations and disclosure Requirements) Regulations, 2015, read with SEBI Circular No.CIR/CFD/FAC/62/2016 dated July 5, 2016.

The preparation of the statement in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, Interim Financial Reporting (Ind AS 34) prescribed under Section 133 of the companies Act, 2013 read with Rule 3 of Companies (Indian Accounting Standard) Rules, 2015 read with SEBI Circular No. CIR/CFD/FAC/62/2016 dated July 5, 2016, is the responsibility of the company management and has been approved by the Board of Directors of the Company. Our Responsibility is to express a conclusion on the statement based on our review.

We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, Review of Interim Financial information performed by the Independent auditor of the Entity issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of Company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement, prepared in accordance with the recognition and measurement principles laid down in the applicable Indian Accounting Standards ("Ind AS") specified under section 133 of the Companies Act, 2013, read with relevant rules issued there under and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, read with SEBI Circular NO. CIR/CFD/FAC/62/2016 dated July 5, 2016, including the manner in which it is to be disclosed, or that it contains any material misstatement.

Place: Hyderabad
Date: 13th, Feb 2019.



For M M Reddy & Co.
Chartered Accountants

M Madhusudhana Reddy
Partner
Membership No. 213077